PHP and Immunotherapy in Metastasized UM

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2029

Conditions
Uveal Melanoma, Metastatic
Interventions
DRUG

Ipilimumab and nivolumab

The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.

DRUG

Melphalan chemosaturation via percutaneous hepatic perfusion

The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.

Trial Locations (1)

2333 ZA

Leiden University Medical Center, Leiden

All Listed Sponsors
lead

Leiden University Medical Center

OTHER